Sökning: WFRF:(Linglart Agnès)
> (2022) >
Burosumab for X-lin...
Burosumab for X-linked hypophosphatemia in children and adolescents : Opinion based on early experience in seven European countries
-
- Mughal, M. Zulf (författare)
- Department of Paediatric Endocrinology and Metabolic Bone Diseases, Royal Manchester Children's Hospital, Manchester, United Kingdom; The Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom
-
- Baroncelli, Giampiero I. (författare)
- Division of Pediatrics, Endocrine Unit, ERN-BOND Representative, Department of Obstetrics, Gynecology and Pediatrics, University-Hospital, Pisa, Italy
-
- de Lucas-Collantes, Carmen (författare)
- Servicio Nefrología, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain
-
visa fler...
-
- Linglart, Agnès (författare)
- AP-HP, Endocrinology and Diabetes for Children, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Filière OSCAR, Bicêtre Paris Saclay Hospital, Paris, France; Platform of Expertise for Rare Disorders, INSERM, Physiologie et Physiopathologie Endocriniennes, Paris Saclay University, Paris, France
-
- Magnolato, Andrea (författare)
- Department of Pediatrics, Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy
-
- Raimann, Adalbert (författare)
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergology and Endocrinology, Medical University of Vienna, Vienna, Austria; Vienna Bone and Growth Center, Vienna, Austria
-
- Santos, Fernando (författare)
- Hospital Universitario Central de Asturias (HUCA), University of Oviedo, Oviedo, Spain
-
- Schnabel, Dirk (författare)
- Center for Chronic Sick Children, Pediatric Endocrinology, Charitè, University Medicine, Berlin, Germany
-
- Shaw, Nick (författare)
- Department of Endocrinology and Diabetes, Birmingham Women's and Children's NHS Foundation Trust, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom
-
- Nilsson, Ola, 1970- (författare)
- Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Division of Pediatric Endocrinology, Department of Women's and Children's Health , Karolinska Institutet and University Hospital, Stockholm, Sweden; Department of Pediatrics, University Hospital, Örebro, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2023-01-31
- 2022
- Engelska.
-
Ingår i: Frontiers in Endocrinology. - : Frontiers Media S.A.. - 1664-2392. ; 13
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions via Within3, a virtual online platform. Points of discussion related to patient selection criteria, burosumab starting dose, dose titration and treatment monitoring. Our discussions revealed that criteria for selecting children with XLH varied across Europe from all children above 1 year to only children with overt rickets despite conventional treatment being eligible. We initiated burosumab dosing according to guidance in the Summary of Product Characteristics, an international consensus statement from 2019 and local country guidelines. Dose titration was primarily guided by serum phosphate levels, with some centers also using the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR). We monitored response to burosumab treatment clinically (growth, deformities, bone pain and physical functioning), radiologically (rickets and deformities) and biochemically (serum phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, urine calcium-creatinine ratio and TmP/GFR). Key suggestions made by our group were initiation of burosumab treatment in children as early as possible, from the age of 1 year, particularly in those with profound rickets, and a need for clinical studies on continuation of burosumab throughout adolescence and into adulthood.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- XLH
- adolescents
- burosumab
- children
- dosing
- growth plate closure
- rickets
- transition
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Mughal, M. Zulf
-
Baroncelli, Giam ...
-
de Lucas-Collant ...
-
Linglart, Agnès
-
Magnolato, Andre ...
-
Raimann, Adalber ...
-
visa fler...
-
Santos, Fernando
-
Schnabel, Dirk
-
Shaw, Nick
-
Nilsson, Ola, 19 ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Frontiers in End ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet